中药贴膏剂龙头要“跨界”？羚锐制药拟7.82亿元收购银谷制药，股价盘中跌近4%

Acquisition Overview - Lingrui Pharmaceuticals plans to acquire 100% equity of Yingu Pharmaceutical for a valuation not exceeding RMB 782.12 million [2] - The acquisition will be funded by Lingrui's own capital, with RMB 772 million in cash reserves as of September [3] - A 60-day exclusivity period has been agreed upon, during which Yingu cannot negotiate with other potential buyers [2] Target Company Profile - Yingu Pharmaceutical, established in 2007, is a high-tech enterprise specializing in innovative and generic chemical drugs [4] - The company holds 13 patents with 2 more pending, and has production facilities in Beijing and Hebei [4] - Yingu has developed China's first high-selective anticholinergic receptor antagonist, Bilitin, and several other innovative drugs [5] Strategic Rationale - The acquisition aligns with Lingrui's strategic plan to expand its business scope and create synergies [6] - Post-acquisition, Yingu will be consolidated into Lingrui's financial statements [6] - The deal is subject to further due diligence, negotiation, and regulatory approvals [6] Market Reaction - Lingrui's stock price dropped by 3.98% on the morning following the announcement [7]